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We studied CD8 T cell responses against HIV-1, cytomegalovirus,
Epstein–Barr virus, and inﬂuenza in 128 subjects and demonstrate
that polyfunctional CD8 T cell responses, also including IL-2 pro-
duction and Ag-speciﬁc proliferation, are predominantly driven by
virus epitopes restricted by HLA-B alleles. Interestingly, these
protective CD8 T cells are equipped with low-avidity T cell recep-
tors (TCRs) for the cognate virus epitope. Conversely, HLA-A-
restricted epitopes are mostly associated with ‘‘only effector’’
IFN--secreting, with cytotoxicity, and with the lack of IL-2 pro-
duction and Ag-speciﬁc proliferation. These CD8 T cells are
equipped with high-avidity TCR and express higher levels of the T
cellexhaustionmarkerPD-1.Thus,thefunctionalproﬁleoftheCD8
T cell response is strongly inﬂuenced by the extent to which there
is stimulation of polyfunctional (predominantly restricted by
HLA-B) versus only effector (restricted by HLA-A) T cell responses.
These results provide the rationale for the observed protective role
of HLA-B in HIV-1-infection and new insights into the relationship
betweenTCRavidity,PD-1expression,andthefunctionalproﬁleof
CD8 T cells.
HLA genotype  PD-1 expression  functional proﬁle  T cell avidity
C
ertain functions, such as the proliferation capacity and the
secretion of IL-2, appear to be associated with effective T cell
responses (1–6). On the basis of the analysis of IL-2 and IFN-,
three functionally distinct populations of Ag-specific CD4 T cells
(single IL-2, dual IL-2/IFN-, and single IFN-) and two function-
ally distinct populations of CD8 T cells (dual IL-2/IFN- and single
IFN-) have been identified (1, 2, 5–9), and the presence of
IL-2-secreting T cells was consistently associated with the Ag-
specific proliferation capacity (1, 4–6). Recently, the term ‘‘poly-
functional’’hasbeenusedtodefineTcellresponsesthat,inaddition
to typical effector functions such as secretion of IFN-, TNF-, and
MIP-1 and cytotoxic activity, comprise distinct T cell populations
also able to secrete IL-2 and that retain Ag-specific proliferation
capacity (7). The term ‘‘only effector’’ defines T cell responses/
populations able to secrete cytokines such as IFN-, TNF-, and
MIP-1 and endowed with cytotoxic activity but lacking IL-2 and
proliferation capacity (7). Of interest, several studies have demon-
strated that polyfunctional, and not only effector, T cell responses
were associated with protective antiviral immunity (1–3, 5–9).
Several studies have clearly demonstrated the importance of
HLA genotype in influencing the evolution of HIV and the
progression of HIV-associated disease. In particular, certain
HLA-B alleles are most closely associated with nonprogressive
disease and low viral load or disease and have a dominant involve-
ment on the clinical course of HIV-associated disease (10, 11).
Because polyfunctional CD8 T cell responses are associated with
protective antiviral immunity and nonprogressive HIV disease and
because HLA-B influences the outcome of HIV disease, it was of
interest to investigate the relationship between HLA-B and poly-
functional responses to determine whether HLA-B influenced the
generation of polyfunctional CD8 T cell responses. To test the
hypothesis, we performed a comprehensive four-digit character-
ization of HLA genotype and of virus-specific CD8 T cell responses
against HIV-1, CMV, EBV, and influenza (Flu) in 128 subjects
comprising 69 HIV-negative, 50 HIV-1-infected subjects with
chronic progressive infection, and 9 HIV-1-infected subjects with
nonprogressive disease.
Results
CD8 T cell responses were studied in a cohort of 50 HIV-1-
chronically infected subjects with progressive disease 1 year after
initiation of antiviral therapy. The 50 subjects had gag-specific CD8
T cell responses. We performed four-digit HLA genotype, and it is
importanttomentionthattheproportionofHLAallelesassociated
withlowrelativehazardsofprogression(10)inthestudypopulation
was not increased over what are the expected natural frequencies
in a white Caucasian population (2 of 50 with HLA-B*5701 and 6
of 50 with HLA-B*2705). Furthermore, the long-term nonprogres-
sors (LNTPs) were not a subset of the main population studied.
The initial epitope characterization was performed on the basis
of potential epitopes inferred from the HLA genotype (12, 13).
HLA restrictions and gag-derived peptides inducing specific re-
sponses are shown in supporting information (SI) Table 1.O nt h e
basis of this analysis, 20 subjects showed polyfunctional CD8 T cell
responses, and 30 subjects showed only effector responses. Repre-
sentative examples of typical polyfunctional CD8 T cell responses,
as indicated by the presence of dual IL-2/IFN-, single IFN-,
proliferating, and CD8 T cells with degranulation activity, and of
only effector CD8 T cells, as indicated by the presence of single
IFN- and CD8 T cells with degranulation activity but lacking
proliferation capacity and IL-2 secretion, are shown in Fig. 1.
CD8 T cell responses against 82 gag epitopes and 39 peptide-
HLA associations were identified. The number of responses in-
duced by individual gag epitopes and their frequency of response
areshowninSITable2.TheHLArestrictionsandepitopemapping
were experimentally assessed using HLA matched and mismatched
BCL in 16 of the 39 gag-specific peptide–HLA associations iden-
tified (SI Fig. 7). The HLA class I genotype of the patients and of
the HLA-matched and mismatched BCL used to confirm HLA
restrictions are shown in SI Table 3. Epitopes were randomly
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experimentally confirmed (12, 13).
We then investigated the association between HLA-A/B alleles
and both only effector and polyfunctional CD8 T cell responses.
The large majority (33 of 42, 79%) of epitopes restricted by HLA-A
were associated with only effector CD8 T cell responses compared
with only 9 of 42 (21%) epitopes associated with polyfunctional
responses (Fig. 2A). Of interest, 45% of epitopes restricted by
HLA-B were associated with polyfunctional CD8 T cell responses,
and 55% were associated with only effector CD8 T cell responses
(Fig. 2A). The differences in the association between HLA-A and
HLA-B and polyfunctional CD8 T cell responses were highly
significant (P  0.012).
We then determined whether there was a different distribution
ofHLAalleleswithinsubjectswithpolyfunctionalandonlyeffector
responses and a preferential association between certain HLA
alleles and polyfunctional CD8 T cell responses. There were not
significant differences in the distribution of HLA-A alleles. With
regard to HLA-B alleles, HLA-B27 was significantly enriched in
subjects with polyfunctional responses and HLA-B35 was signifi-
cantly enriched in those with only effector responses (SI Fig. 8).
In-depth analysis of the total 82 gag-specific responses showed
that amongst the 42 responses restricted by HLA-A, the polyfunc-
tional gag-specific CD8 T cell responses were restricted by HLA-
A*0201 (n  6), HLA-A*0301 (n  2), and HLA-A*3001 (n  1)
(Fig. 2B); among the 40 responses restricted by HLA-B, the
Fig. 1. Functional proﬁle of HIV-1-speciﬁc CD8 T cell populations. (A) Representative ﬂow cytometry proﬁles of a polyfunctional response deﬁned by IL-2 and
IFN-secretion,degranulationactivity(asmeasuredbyCD107amobilization),andproliferationcapacity(asmeasuredbyCFSEdilution).(B)Representativeﬂow
cytometry proﬁles of an only effector CD8 T cell response deﬁned by IFN- secretion and degranulation activity and by the lack of IL-2 secretion and of
proliferation capacity. Staphylococcal enterotoxin serotype B (SEB) was used as positive control.
Fig. 2. Relationship between HLA-A and HLA-B and the functional proﬁle of HIV-1-speciﬁc CD8 T cell populations. (A) Proportion of HIV-1 gag epitopes restricted
byHLA-AandHLA-Binducingpolyfunctional(positiveforIL-2)andeffector(negativeforIL-2)CD8Tcellresponses.(B)AssociationbetweenHLA-AandHLA-Bgenotypes
and polyfunctional CD8 T cell responses. (C) Hierarchy within HLA-B alleles in their association with polyfunctional responses. (D) Analysis of HLA-A restricted only
effector and HLA-B restricted polyfunctional gag-speciﬁc CD8 T cell responses within the same blood samples. IL-2 and IFN- secretion was assessed in three patients
selected on the basis of the simultaneous presence of polyfunctional and only effector responses restricted by HLA-B and HLA-A alleles, respectively.
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of HLA-B genotypes, including HLA-B*0702 (n  3), HLA-
B*0801 (n  5), HLA-B*2705 (n  2), HLA-B*4001/2 (n  3),
HLA-B*5201 (n  1), and HLA-B*5701 (n  4) (Fig. 2B).
Although HLA-B alleles, such as HLA-B57 and -B27, which have
been shown to be associated with slow disease progression to AIDS
(10), were associated with polyfunctional responses, it is important
to underscore that they are not solely responsible for the prefer-
entialassociationbetweenHLA-Bandpolyfunctionalresponses.In
fact, if HLA-B57 and -B27 were not included in the analysis, then
the difference between HLA-A and HLA-B regarding the associ-
ation with polyfunctional responses was lost (P  0.59). Similarly,
the removal of other HLA-B alleles from the analysis led to a loss
ofassociationbetweenHLA-Bandpolyfunctionalresponsesaswell
(P  0.13). Therefore, the data do not support the effects of
specified single HLA-B alleles and rather indicate a broader, more
generic effect of HLA-B group alleles and the presence of a
hierarchy within HLA-B alleles in their association with polyfunc-
tional responses (Fig. 2C).
In further support of this hypothesis, we analyzed HLA-A- and
HLA-B-restricted CD8 T cell responses for polyfunctionality in the
same blood sample in three patients. We consistently observed that
HLA-B-restricted epitopes induced polyfunctional CD8 T cell
responses, whereas HLA-A restricted epitopes only effector CD8 T
cell responses (Fig. 2D).
A slight difference in viral load and not in CD4 T cell counts
betweenthe20subjectswithpolyfunctionalandthe30subjectswith
only effector CD8 T cell responses (4.54  0.12 vs. 4.86  0.11 Log
RNA copies per milliliter, P  0.04; 588  60 vs. 515  59 CD4 T
cells per microliter, P  0.2, respectively) was present before
therapy. However, virus replication was effectively suppressed in
both groups after antiviral therapy.
Taken together, these results indicate that HLA-B genotype
influenced the generation of polyfunctional profile of CD8 T cells.
Theyalsoconfirmedthatsuppressionofviralloadwasnotsufficient
forthegenerationofpolyfunctionalresponsesbecauseonlyHLA-B
responses, and not HLA-A-restricted responses, were associated
with polyfunctional responses within the same patient.
WetheninvestigatedtheimportanceofHLA-Bin(i)shapingthe
CD8 T cell response in HIV-1-infected individuals with nonpro-
gressive disease, i.e., LTNPs, and (ii) in virus-specific CD8 T cell
responses other than HIV. A large number of virus-specific (HIV-
1-specific in LTNPs, CMV-, EBV- and Flu-specific) CD8 T cell
responses restricted by HLA-A (n  85) or HLA-B (n  81) were
then investigated (CMV-, EBV- and Flu-specific epitopes are listed
in SI Table 4). After Ag-specific stimulation, the percentage of dual
IL-2/IFN--secreting cells, but not of single IFN--secreting cells,
was significantly higher in the epitopes restricted by HLA-B com-
pared with HLA-A in all four models of virus-specific CD8 T cell
response (Fig. 3). These results indicate that HLA-B has a general
role in governing the generation and the magnitude of polyfunc-
tional CD8 T cell responses.
Wethencharacterizedeventualdifferencesintheresponsiveness
of CD8 T cell populations restricted by HLA-A and HLA-B. For
these purposes, we investigated the T cell receptor (TCR) avidity
for the cognate epitope of polyfunctional and only effector CD8 T
cell populations. The TCR avidity was determined in CMV- and
EBV-specific CD8 T cells obtained from HIV-negative healthy
donors and in HIV-1-specific CD8 T cells obtained from subjects
with progressive disease.
TCR avidity was initially analyzed in HLA-A vs. HLA-B re-
stricted CD8 T cell responses. Subject nos. 524 and 525 had an
EBV-specific CD8 T cell response against the IVTDFSVIK and
RAKFKQLL peptides restricted by HLA-A11 and by HLA-B8,
respectively. Patients no. 8 and no. 12 had an HIV-1-specific CD8
T cell response against the FLGKIWPSYK and ISPRTLNAW
peptides restricted by HLA-A2 and by HLA-B57, respectively.
Following Ag-specific stimulation with decreasing peptide con-
centration and assessment of total IFN- secreting CD8 T cells,
there was a rapid loss in the percentage of RAKFKALL- and
ISPRTLNAW-specific CD8 T cells restricted by HLA-B8 and
HLA-B57 compared with IVTDFSVIK- and FLGKIWPSYK-
specific CD8 T cells restricted by HLA-A11 and HLA-2 (Fig. 4A).
The significant difference between CD8 T cell responses restricted
by HLA-A and HLA-B in the avidity for the cognate epitopes was
confirmed in a larger number of responses (Fig. 4 B and C).
We then analyzed TCR avidity on the two functionally distinct
CD8 T cell populations, i.e., dual IL-2/IFN- and single IFN-
(representative subject no. 525 is shown). As shown in Fig. 5, after
Ag-specific stimulation with decreasing peptide concentration and
Fig. 3. Inﬂuence of HLA-B on CD8 T cell responses against CMV, EBV, Flu, and HIV-1 in LTNP. Cumulative data on the percentage of single IFN- and dual
IL-2/IFN-CD8TcellsafterstimulationwithHIV-1-,CMV-,EBV-,andFlu-derivedpeptidesrestrictedbyHLA-AandHLA-Bareshown.Cumulativepercentagedata
are expressed as the mean  SE.
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percentage of dual IL-2/IFN- compared with single IFN--
secreting CD8 T cell populations (Fig. 5A). The significant differ-
ence between IL-2/IFN- and single IFN- in the avidity for the
cognate epitopes were confirmed for 27 CMV/EBV-specific re-
sponses in healthy subjects (Fig. 5B). A similar difference was
observed for HIV-1-specific responses (Fig. 5B). We then com-
pared the TCR avidity of IL-2/IFN- and single IFN- CD8 T cell
populations on the basis of the HLA restriction. Of interest, the
EC50 of both IL-2/IFN- and single IFN--secreting virus-specific
CD8 T cell populations recognizing virus epitopes restricted by
HLA-B was significantly higher compared with that of epitopes
restricted by HLA-A (Fig. 5C).
Taken together, these results indicate that overall virus-specific
CD8 T cell populations recognizing virus epitopes restricted by
HLA-B are equipped with lower avidity TCR for the cognate
epitopes compared with those recognizing epitopes restricted by
HLA-A.
We have also analyzed the expression of programmed death 1
(PD-1) that has been recently shown to be selectively up-regulated
by exhausted CD8 T cells during chronic virus infections (14–17).
PD-1 expression was assessed in HLA-B restricted polyfunctional
versus HLA-A-restricted only effector HIV-1-specific CD8 T cell
populations. PD-1 expression was significantly up-regulated in
HLA-A-restricted only effector compared with HLA-B-restricted
polyfunctional CD8 T cell populations (Fig. 6 A and B). Repre-
sentative examples and cumulative data are shown (Fig. 6 Aand B).
PD-1 expression on HLA-B-restricted polyfunctional HIV-1-
specific CD8 T cell populations were similar to those observed in
EBV-specific CD8 T cell populations from HIV-negative subjects
(Fig. 6B). Of interest, there was a significant negative correlation
between the proportion of HIV-1-specific IL-2-secreting CD8 T
cell populations and PD-1 expression (Fig. 6C).
Discussion
The results reported here provide insights into the delineation of
the factors influencing the functional diversity of Ag-specific
CD8 T cells and demonstrate that the HLA genotype is an
important factor in shaping the functional profile of CD8 T cells.
They also help to shed light on the protective role of HLA-B
genotype in virus infections (10, 11) and on the relationship
between TCR avidity for the cognate epitope and effective/
protective response in chronic virus infection.
The influence of HLA-B in the selection of polyfunctional CD8
T cell responses is strongly supported by two findings: (i) the
generality of the effect of HLA-B to four RNA and DNA viruses
and (ii) the observation that HIV-1-specific HLA-A restricted CD8
T cell responses were only effector and HLA-B-restricted were
polyfunctional CD8 T cell responses within the same patients.
Furthermore, the recent observation of the increased magnitude of
HLA-B-restricted HIV-1-specific CD8 T cell responses (18) can be
extended to polyfunctional CMV-, EBV-, and Flu-specific CD8 T
cell responses, which were significantly greater when virus-specific
epitopes were restricted by HLA-B than HLA-A alleles.
The mechanisms by which HLA-B alleles also induce polyfunc-
tional CD8 T cell responses rather than only effector responses, as
it is mostly the case for HLA-A, and why they confer protection
from HIV-associated disease are unknown. Our present findings
demonstrating that these responses were predominantly induced by
epitopes restricted by HLA-B may provide the rationale for ex-
Fig.4. TCRavidityofHLA-A-andHLA-B-restrictedresponses.(A)RepresentativeexamplesoftheresponsivenessofHLA-AandHLA-BrestrictedEBV-andHIV-1-speciﬁc
CD8 T cell responses after stimulation with decreasing peptides concentrations. Two EBV-derived peptides restricted by HLA-A11 and -B8 and two HIV-1-derived
peptides restricted by HLA-A2 and -B57 were used. (B and C) Cumulative data for EBV/CMV (B) and HIV-1 (C) are shown. The EC50 corresponds to the peptide
concentration needed to achieve a half-maximal response.
Fig. 5. TCR avidity of single IFN- and dual IL-2/IFN- CD8 T cells. (A) Representative example (subject no. 525) of the responsiveness of the single IFN- and
dual IL-2/IFN- CD8 T cells after stimulation with decreasing peptide concentrations of one HLA-B8 restricted EBV-derived peptide (RAKFQLL). (B) Cumulative
data on the TCR avidity of EBV/CMV- and HIV-1-speciﬁc single IFN- and dual IL-2/IFN- CD8 T cells. (C) Cumulative data on the TCR avidity of virus-speciﬁc
(HIV-1CMVEBV) single IFN- and dual IL-2/IFN- CD8 T cells recognizing HLA-A- and HLA-B-restricted epitopes. The EC50 corresponds to the peptide
concentration needed to achieve a half-maximal response.
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such as HIV (10, 11) and more recently HCV (19). In this regard,
it is currently debated whether the protective effect is limited to few
alleles such as HLA-B57 and HLA-B27 or whether it is a broader
effect of HLA-B alleles. Our observations regarding polyfunctional
responses to HIV-1, EBV, CMV, and Flu are not explained simply
by the effect of specified single HLA-B alleles but by a broader,
more generic effect of HLA-B group alleles. Although certain
HLA-B alleles, such as HLA-B27 and HLA-B57, associated with
low relative hazard to AIDS, were enriched in subjects with
polyfunctional gag-specific CD8 T cell responses, these responses
were not sufficient to support the significant difference between
HLA-A and HLA-B alleles in selecting for polyfunctional CD8 T
cell responses. As previously shown for the association between
HLA-B alleles and low relative hazard to AIDS (11), the present
results indicate a hierarchy within HLA-B alleles in influencing the
generation of polyfunctional CD8 T cell responses. HLA-B alleles
such as HLA-B57 and -B27 were associated with polyfunctional
responses in 100% of cases, HLA-B7, -B40, and -B8 were
associated with polyfunctional responses in 50%, and HLA-B52
was associated with polyfunctional responses in 30% of cases.
Our TCR avidity results provide new insights into understanding
the relationship between TCR avidity of CD8 T cells, their func-
tional profile, and disease control in chronic virus infections. A
recentstudy(18)failedtoshowadifferenceinTCRaviditybetween
HLA-A- and HLA-B-restricted epitopes in HIV-1 infection. How-
ever, there was no functional characterization of only effector and
polyfunctional responses. Our results indicate that polyfunctional
CD8 T cell populations are equipped with low-avidity TCR com-
pared with only effector CD8 T cell populations. However, it is
worth mentioning that, to measure TCR avidity, we have used
reference strain sequences of the epitopes for stimulation. There-
fore, we cannot exclude that, in some instances, the peptide
sequences used do not perfectly correspond to the sequences of the
circulating virus in vivo. However, we have shown the same phe-
nomenon also for responses to other virus infections in which
sequence changes and partial escape from recognition are highly
unlikely and in which it is also unlikely that changes in the epitope
sequences of the circulating virus would occur more frequently for
HLA-B- than for HLA-A-restricted epitopes.
Because polyfunctional CD8 T cell responses have been clearly
shown to be associated with better disease control in chronic virus
infections in humans and mice, these results may appear to be
somewhat in conflict with the current paradigm of higher avidity
corresponding to greater efficacy of the CD8 T cell response
(20–22). This paradigm is predominantly based on the observation
that higher avidity cytotoxic CD8 T cells have superior antitumor
activity and mediate effective antiviral activity during the acute
phase of viral infection (20–22).
It is not our intention to challenge the relationship between
higher avidity CD8 T cells and superior antitumor and antiviral
activity. However, we want to propose that the superiority of higher
avidity CD8 T cells may be substantially undermined under con-
ditions of Ag persistence and high levels of viral load. This
hypothesis is supported by two observations: (i) higher functional
avidity of CD8 T cells is most strongly associated with escape
mutations (23–25) in both SIV and HIV infections, and (ii) higher
avidity CD8 T cells are more susceptible to activation-induced cell
deathandexhaustion(26,27).Ourresultsindicatethatonlyeffector
CD8 T cell populations were equipped with high-avidity TCR and
expressedhigherPD-1levels,furthersupportingourhypothesisthat
these cells are at risk of exhaustion and thus that their antiviral
activity may be substantially impaired.
Polyfunctional CD8 T cell populations were equipped with
low-avidity TCR and expressed low PD-1 levels. Although their
intrinsic antiviral activity is likely inferior to the higher avidity CD8
T cell populations, it is possible that, under conditions of Ag
persistence and high Ag load, they may be more suitable for
mediating at least partial viral control. Because of being equipped
with low-avidity TCR, polyfunctional CD8 T cell populations are
less susceptible to exhaustion and less efficient in driving escape
mutants. In support of the hypothesis that low-avidity TCR poly-
functional CD8 T cells may be more efficient under conditions of
Agpersistence,recentstudiesdealingwithantitumoractivityduring
tumor persistence showed that tumor control was associated with
cytotoxic CD8 T cells equipped with low-avidity TCR (28) and the
accumulation of low-avidity antimelanocortin receptor 1 CD8 T
cells in benign skin lesions of melanoma-related depigmentation
(29). Similarly, polyfunctional CD8 T cells are invariably found in
chronic virus infections with effective virus control, such as HIV-1
infection in LTNP, CMV, and EBV infections. Furthermore,
IL-2/IFN--secreting CD8 T cells have been shown to mediate
effective antiviral activity comparable with typical effector CD8 T
cells in the LCMV model (30).
Therefore, notwithstanding the intrinsic superior antiviral activ-
ity of higher avidity TCR CD8 T cells, low-avidity TCR polyfunc-
tional CD8 T cells may be more fit in providing disease control
during chronic virus infection.
Finally, these results may provide insights into the development
of strategies for the design of T cell vaccines that may select
predominantly for the generation of polyfunctional CD8 T cell
responses.
Materials and Methods
Study Groups. Fifty subjects with progressive chronic HIV-1 infec-
tion were recruited in this study. All patients were enrolled in
clinical trials, receiving antiviral therapy with nucleoside and pro-
tease inhibitors (31). At baseline (before the initiation of antiviral
therapy), the median CD4 T cell count was 411 cells per microliter,
Fig. 6. PD-1 expression. (A) Representative ﬂow cytometry proﬁles of PD-1 expression on HLA-B restricted polyfunctional and HLA-A restricted only effector
HIV-1-speciﬁc CD8 T cells. PD-1 expression was assessed on the total IFN- secreting CD8 T cells. PD-1 expression on CD8 T cells after anti-CD3 stimulation was
usedascontrol.(B)CumulativedataontheexpressionofPD-1inthetotalIFN-secretingCD8TcellsinHIV-infectedsubjectswithHIV-1-speciﬁcHLA-BandHLA-A
restricted responses and in HIV-negative subjects with EBV-speciﬁc responses are also shown. (C) Correlation between the proportion of HIV-1-speciﬁc IL-2
secreting CD8 T cells and PD-1 expression.
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per milliliter. One year after initiation of antiviral therapy, median
CD4 T cell count were 621 cells per microliter, and median plasma
viremia was 20 HIV-1 RNA copies per milliliter. A modified PCR
assay with a limit of detection of 20 copies (32) was used in patients
with levels of viremia 50 copies. Nine HIV-1-infected patients
with nonprogressive disease, i.e., LTNP, as defined by documented
HIV-1 infection since 14 years, stable CD4 T cell counts 500
cells per microliter (median: 1,302), and plasma viremia 1,000
HIV-1 RNA copies per milliliter (median: 17) were also included.
In addition, blood from 69 HIV-negative subjects was obtained
either from the local blood bank (Lausanne, Switzerland) or from
laboratory coworkers. The studies were approved by the Institu-
tional Review Board of the Centre Hospitalier Universitaire Vau-
dois and informed consent was obtained from each patient.
Synthetic Peptides.AllofthepeptidesusedinthisstudywereHPLC
purified (80% purity). Fine epitope mapping was performed on
thepredictedHLAgenotypeaccordingtotheLosAlamosdatabase
(12, 13) and on the HLA class I genotype of the patients. On the
basis of these analyses, 32 HLA class I restricted gag epitopes were
identified(SITable2).Furthermore,asetofpeptides(n28)most
frequently recognized in CMV, EBV, and Flu infection were used
toassessthefunctionalprofileofvirus-specificCD8Tcellresponses
(33, 34).
Detection of IFN- and IL-2 Secretion (ICS). Cryo-preserved blood
mononuclear cells (1–2  106) were stimulated overnight as de-
scribed in ref. 6. At the end of the stimulation period, cells were
washed, permeabilized, and then stained with CD8-PerCP-Cy5.5,
CD4-FITC, IFN--APC, and IL-2-PE (BD Pharmingen, San Di-
ego, CA). For PD-1 expression, cells were stained with anti-PD-1-
FITC, CD8-PerCP-Cy5.5, and IFN--APC antibodies (BD Pharm-
ingen). Data were acquired on a FACScalibur or on an LSRII and
were analyzed using CellQuest and DiVa softwares (BD Pharm-
ingen), respectively. The number of lymphocyte-gated events
ranged between 105 and 106 in the flow cytometry experiments
shown. With regard to the criteria of positivity of ICS, the back-
ground in the unstimulated controls never exceeded 0.01% to
0.02%. To be considered positive, an ICS had to have a background
20% of the total percentage of cytokine-positive cells in the
stimulated samples.
Functional Avidity. The stimulation was performed as described in
ref. 6. The functional avidity of responses was assessed by perform-
ing limiting peptide dilutions and determining the peptide concen-
tration required to induce half-maximal responses in in vitro assays
(18). Peptides were added in serial dilutions ranging from 1 g/ml
to 1 pg/ml to ICS assays as described above. Both IFN-- and
IL-2-secretingCD8Tcellsweremeasured.EC50wasdeterminedas
the peptide concentration needed to achieve a half-maximal
response.
Degranulation Activity (CD107a Mobilization). Cryo-preserved blood
mononuclear cells (1–2  106) were stimulated for6hi n1m lo f
complete media (RPMI  10% FBS) in the presence of Golgistop
(1 l/ml; BD Pharmingen), Golgiplug (1 l/ml; BD Pharmingen),
CD28Ab(0.5g/ml;BDPharmingen),CD107a-PE(pretittered
volume; BD Pharmingen) and 1 g/ml peptide as described in ref.
7. SEB stimulation (200 ng/ml) served as positive control. At the
end of the stimulation period, cells were washed, permeabilized,
and stained as described in ref. 7. The following Abs were used in
combination: CD14-FITC, CD16-FITC, CD19-FITC, CD69-
PerCP, IFN--APC, CD3-ECD, and CD8-Pacific blue.
Ex Vivo Proliferation Assay. Ag-specific proliferation was deter-
mined using 5,6-carboxyfluorescein succinimidyl ester (CFSE)
(Molecular Probes, Eugene, OR) as described in ref. 6. At day 5,
cells were harvested and stained with CD4-PerCP-Cy5.5 (BD
Pharmingen) and CD8-APC (BD Pharmingen). Cells were fixed
with CellFix (BD Pharmingen) and acquired on an LSRII (BD
Pharmingen).
HLA Class I Typing. Four-digit HLA class I genotyping was per-
formed by direct sequencing methods as described in ref. 35. The
data were analyzed and alleles were assigned using Assign-SBT
version 3.5 (Conexio Genomics, Applecross, Australia).
Statistical Analysis. Statistical analysis was done using GraphPad
(San Diego, CA) Prism version 3.0 and Excel (Microsoft, Red-
mond, WA). Statistical significance (P values) of the results was
calculated by two-tailed t test. A two-tailed P value of 0.05 was
considered significant. The correlations among variables were
tested by least-squares regression analysis. The association between
HLA-A/B alleles and both only effector and polyfunctional CD8 T
cell responses on the 82 gag epitopes was determined by 2 test
(  0.05).
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